SCHEMBL2908515

SCHEMBL2908515

Cc1nc(N)nc(N2Cc3ccc(C(=O)O)cc3C2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.45
HRH4 Q9H3N8 3/20 0.44
TDP1 Q9NUW8 2/20 0.39
HDAC1 Q13547 1/20 0.39
KDM4E B2RXH2 3/20 0.38
GAA P10253 3/20 0.38
HSD17B10 Q99714 2/20 0.38
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSP90AA1 P07900 5/20 0.38
NR4A1 P22736 1/20 0.38
HSP90AB1 P08238 1/20 0.37
HTT P42858 1/20 0.37
NAMPT P43490 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
MTOR P42345 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24173004 0.75 GABRP (0.45) ADORA2ATDP1KDM4EGAAHSD17B10
SCHEMBL3018437 0.71 EPHX2 (0.47) HRH4KDM4EL3MBTL1ALDH1A1HTT
SCHEMBL2513586 0.70 HRH4 (0.67) HRH4
SCHEMBL19339147 0.69 ALDH1A1 (0.53) TDP1KDM4EGAAHSD17B10POLB
SCHEMBL3313453 0.69 ALDH1A1 (0.53) TDP1KDM4EPOLBALDH1A1NAMPT
SCHEMBL7277193 0.67 NOTUM (0.58) TDP1KDM4EPOLBALDH1A1NAMPT
SCHEMBL1075113 0.66 ALDH1A1 (0.53) TDP1KDM4EGAAPOLBL3MBTL1
SCHEMBL2900973 0.66 EPHX2 (0.47) KDM4EL3MBTL1ALDH1A1
SCHEMBL15142217 0.65 ALDH1A1 (0.49) TDP1KDM4EPOLBALDH1A1NAMPT
SCHEMBL20178702 0.65 NAMPT (0.52) TDP1POLBL3MBTL1ALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100210655-A1 NOVEL sEH INHIBITORS AND THEIR USE GLAXOSMITHKLINE LLC 2010-08-19 US disclosed
US-20100210655-A1 NOVEL sEH INHIBITORS AND THEIR USE GLAXOSMITHKLINE LLC 2010-08-19 US disclosed
US-20100210655-A1 NOVEL sEH INHIBITORS AND THEIR USE GLAXOSMITHKLINE LLC 2010-08-19 US disclosed
EP-2217068-A1 NOVEL sEH INHIBITORS AND THEIR USE GlaxoSmithKline LLC (US) 2010-08-18 EP disclosed
WO-2009049154-A1 NOVEL sEH INHIBITORS AND THEIR USE SMITHKLINE BEECHAM CORPORATION (US) 2009-04-16 WO disclosed
WO-2009049154-A1 NOVEL sEH INHIBITORS AND THEIR USE SMITHKLINE BEECHAM CORPORATION (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210655-A1 NOVEL sEH INHIBITORS AND THEIR USE EPHX1, NCEH1, FAH ADORA2A 2664/4885HRH4 50/4885TDP1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.